GlassScriptPhysician profile
Thomas Arthur Upshaw
NPI 1306002142
$3,764.01
in general payments reported to CMS, 2019-2025
20 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $333 · 2021: $645 · 2022: $404 · 2023: $461 · 2024: $777 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,055.41 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.66 | 2021-2025 | Caplyta |
| Allergan, INC. | $375.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $317.55 | 2022-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $299.85 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $191.39 | 2025 | Cobenfy |
| Alkermes, INC. | $148.96 | 2022-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $142.79 | 2019-2024 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $135.49 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $131.82 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $129.42 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $112.11 | 2019-2025 | Nuplazid |
| Axsome Therapeutics, INC. | $78.25 | 2023-2024 | Auvelity, Sunosi |
| Lundbeck LLC | $67.81 | 2020-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $55.37 | 2022-2024 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $44.11 | 2021 | |
| Almatica Pharma LLC | $39.55 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $31.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.28 | 2021 | |
| Kaleo, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Upshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.